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Abstract 
Background: Paraoxonase-1, an organophosphorous-hydrolyzing enzyme, was shown to provide protection against 
organophosphates poisoning in vivo. In vitro findings suggest that the phytoalexin resveratrol can elevate paraoxo-
nase-1 levels and thus may provide protection against organophosphate poisoning. This study was conducted to 
evaluate the effect of prolonged resveratrol intake on paraoxonase-1 levels in rats, and its role as a potential prophy-
lactic treatment in organophosphate poisoning.
Methods: 30 adult male albino Sprague–Dawley rats were randomly assigned into three groups: rats receiving no 
resveratrol (Control group, n = 10), rats treated once daily with oral gavage of ethanol only (Sham group, n = 6), and 
rats treated once daily with oral gavage of resveratrol (50 mg/kg) (Study group, n = 14). Following 2 weeks of feeding, 
all rats were exposed to 1.4LD50 paraoxon (450 mg/kg, intramuscular; 0.5 ml/kg) and monitored for severity of clinical 
signs and mortality. Paraoxonase-1 activity level was recorded in the beginning of the study and 2 weeks later, just 
before exposure to paraoxon.
Results: We found a significant decrease in paraoxonase-1 activity levels in all groups compared to baseline levels 
(p = 0.05), but no significant difference was observed between the study group and the controls (p = 0.7). Following 
exposure to paraoxon, all animals suffered from severe convulsions and died within minutes.
Conclusions: Following resveratrol intake in rats, paraoxonase-1 activity levels decreased. We found no beneficial 
effects in using resveratrol as a prophylactic medical countermeasure.
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Resveratrol, PON-1
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Organophosphate (OP) nerve agents (NAs) pose an 
imminent threat to both warfighters and civilian popu-
lation [1]. Due to the toxic nature of NAs, efforts are 
aimed at introducing advanced pre-treatment and pro-
phylactic medical countermeasures to the field, which 
will enable enhanced survival with less morbidity of sol-
diers in case of exposure. Pyridostigmine bromide is an 
accepted pre-treatment measure [2]. However, it pro-
vides only minor protection against OP poisoning, and 
helps mainly through enhancement of the protection 
provided by the post exposure antidotal mixture [2]. It 
does not protect from OP-induced major CNS symptoms 
and is not considered to be a prophylactic measure [3]. 
These drawbacks have resulted in active search of substi-
tute compounds.
An ideal prophylactic compound will enable sufficient 
levels of functional cholinesterase; is expected to be 
active against a wide range of OPs and NAs; provide pro-
tection by itself, even without any post-exposure treat-
ment; can be taken in a simple way; have a high safety 
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profile and without side-effects; and will provide a long-
lasting effect [4–6].
There are several families of prophylactic compounds, 
defined based on their mode of action. Detoxifying pro-
phylactic compounds include stoichiometric and cata-
lytic bioscavengers. Stoichiometric scavengers bind 
permanently and neutralize the OPs. These include ace-
tylcholine esterase (AChE) and butyrylcholine esterase 
(BChE), with effects against all OPs, including NAs [7]. 
Several transgenic and recombinant systems were devel-
oped so far [8, 9] but none have reached full maturity and 
marketing due to several draw-backs, mainly in upscale 
techniques, immunogenicity, shelf life, large quanti-
ties needed for effective treatment, and price. Catalytic 
scavengers include several hydrolytic enzymes [10]. 
Unlike the stoichiometric scavengers, a relatively low 
dose of the catalytic scavengers should suffice to hydro-
lyze large quantities of OPs [11]. Despite good results 
in terms of preventing clinical poisoning [12, 13], these 
compounds are less broad-spectrum in nature, though 
efforts are made to make them as such [14, 15]. One of 
the candidate catalytic scavengers is human paraoxo-
nase-1 (PON-1), a high-density lipoprotein-associated 
calcium-dependent organophosphate-hydrolase [16], 
which is mainly induced and secreted by the liver [17]. 
It was shown already to have a potential protective effect 
against OP poisoning [18]. Moreover, lack of PON-1 in 
mice increased OP toxicity [19]. The induction of this 
endogenous enzyme biosynthesis, has led to increased 
activity of the human PON-1 gene promoter, followed by 
elevated activity of serum PON-1, providing protection 
against OP exposure in rats [18].
The phytoalexin resveratrol is a potent antioxidant that 
displays antiplatelet, anti-neoplastic, anti-inflammatory 
and neuroprotective properties [20, 21], and is commer-
cially available as a food supplement. Gouedard et  al. 
showed increased in  vitro expression of the HuPON-1 
gene following exposure to resveratrol [22]. Moreo-
ver, increased expression of human PON-1 resulted in 
in  vitro protection against soman and sarin simulants 
[23]. To The best of our knowledge there are no published 
data regarding resveratrol’s ability to increase plasma lev-
els of PON-1 in vivo.
The aim of the current preliminary study was to assess 
whether pre-treatment with resveratrol can provide pro-
tection against OP exposure in a rat model.
Methods
Animals
Following institutional review board approval, 30 adult 
male albino Sprague–Dawley rats (300–320  g, Harlan-
biotech, Jerusalem, Israel) were housed under standard 
laboratory conditions in plastic cages, three per cage, in 
a controlled environment with a constant temperature of 
21 ± 2 °C and 12 h light/dark cycles. Food (Teklad certi-
fied global 18 % protein) and water were available ad libi-
tum. All experiments were designed and performed in 
accordance with the statutes from “The guide for the care 
and use of laboratory animals in research” of the Ben-
Gurion University of the Negev. This study complies with 
the Animal Welfare Act and other federal regulations 
which were approved by the Animal Care Committee. All 
procedures were performed under the supervision of a 
veterinarian.
Drugs
Paraoxon was purchased from Sigma Chemical Co. 
(Israel) and diluted in a vehicle containing 40 % propyl-
ene glycol. Resveratrol was purchased in a commer-
cially-available form of capsules, each containing 100 mg 
resveratrol dissolved in ethanol (Solgar, Israel).
Study design
Animals were randomly divided into three groups: (1) 
rats receiving no resveratrol (Control group, n  =  10); 
(2) rats treated once daily with oral gavage of ethanol 
only (Sham group, n = 6); and (3) rats treated once daily 
with oral gavage of resveratrol (50 mg/kg) (Study group, 
n  =  14). Following 2  weeks of feeding, during which 
animals’ weight was followed, all rats were exposed to 
1.4LD50 paraoxon (450 mg/kg, intramuscular; 0.5 ml/kg) 
and monitored for severity of clinical signs and mortality. 
Clinical score was defined as follows: (0) no activity, quiet 
periods; (1) chewing and facial clonus; (2) tremors and 
focal convulsions; and (3) severe generalized tonic–clonic 
convulsions.
Laboratory tests
PON-1 activity level was measured in the beginning of 
the study and 2 weeks after the oral supplementation of 
resveratrol, just before exposure to paraoxon. PON-1 
activity level was analyzed as described by Aviram and 
Rosenblat [24]. Briefly, 5 µl aliquots of serum were ana-
lyzed. The basal assay mixture included 1.0  mM phenyl 
acetate in “activity buffer”. Phenyl acetate hydrolysis was 
kinetically monitored for 3 min (every 15  s) at 270  nm. 
One unit of PON-1 arylesterase activity is equivalent to 
1 µmol of phenyl acetate hydrolyzed/min/ml.
Statistical analysis
Statistical analyses were performed using SPSS V.19 soft-
ware. Data are presented as mean and standard error (SE) 
for continuous variables. Comparisons between groups 
were done using Student’s t test for continuous variables 
and with the Chi square test for categorical variables. 
p < 0.05 was considered significant.
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Results
Out of 10 animals in the control group, one died during 
the two-week period before the poisoning.
Baseline levels of PON-1 activity were similar among 
the treatment, control and sham groups (p = 0.3; Table 1; 
Fig.  1). After 2  weeks of feeding with resveratrol, no 
increase in PON-1 activity level was found. On the con-
trary, all groups demonstrated a small yet significant 
decrease in the enzyme activity levels as compared to 
baseline levels (p = 0.05; Table 1; Fig. 1). No significant 
difference between the groups was demonstrated after 
2  weeks, in comparison to the corresponding baseline 
activity levels (p = 0.7).
A statistically significant and rather steady increase in 
body weight was observed during the 2 weeks of feeding 
(p  <  0.01). No significant difference was noted between 
the study group and both the sham and control groups 
(p = 0.07).
All animals developed severe convulsions (score 3) and 
died, within 1–3  min and 10  min, respectively, follow-
ing paraoxon exposure. Cause of death was respiratory 
failure.
Discussion
Maintaining sufficient levels of functional cholinesterase is 
a major goal of a prophylactic or pre-treatment approach 
against NA poisoning [5]. Other requirements include also 
long-lasting effect, high availability, and lack of side effects. 
These goals could, theoretically, be achieved by various 
means: decreasing the levels of active OP molecules within 
the bloodstream, elevating the levels of cholinesterases 
in the bloodstream and in various tissues, elevating the 
concentration of endogenous and exogenous detoxifying 
enzymes, protecting cholinesterases from inhibition, and 
reactivation of inhibited enzyme [3, 5, 6].
In the current study, based on in  vitro data, we have 
tested the efficacy of pre-treatment with resveratrol in 
a rat model of paraoxon poisoning. During the 14-day 
feeding phase preceding the exposure, we followed the 
animals’ weight. The change in weight implies that no 
serious health effects were caused by resveratrol. How-
ever, when looking at PON-1 activity levels in serum, we 
found no elevation in PON-1 activity levels in animals 
pre-treated with resveratrol. Also, all animals, including 
the study group, died shortly after exposure to paraoxon 
with no difference in survival time. Because of the rapid 
death, neither a comparison between the groups, nor an 
examination of clinical signs over an extended period of 
time after poisoning was possible.
Table 1 PON-1 activity levels, before exposure (baseline, 0) 
and 14 days after exposure to 1.4LD50 paraoxon
Time (days) Average enzyme  
activity (U/ml)
P
Control group (n = 9) 0 689.8 ± 16.9 0.05
14 657.6 ± 35.3
Treatment group  
(n = 14)
0 670.5 ± 13.6 0.05
14 607.6 ± 28.3
Sham group (n = 6) 0 650.1 ± 20.8 0.05
14 615.6 ± 43.2
Fig. 1 PON-1 activity levels, baseline (before exposure) and 14 days after exposure; *P = 0.05
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There are several possible explanations for these 
results: (1) taking into consideration the lack of infor-
mation regarding the therapeutic window of resvera-
trol in OP poisoning, the dose given was possibly too 
low to provide protection. We adjusted the dose of the 
compound based on the report of Williams et  al. that 
administered resveratrol to rats at doses of 50–500 mg/
kg/day during a 28-days period with no side effects [25]. 
The lack of a dose–response curve may lead to the theo-
retical possibility that the resveratrol dose was not suf-
ficient in order to sufficiently-influence PON1 levels. 
However, the fact that PON1 levels did not increase and 
even significantly decreased during the treatment time 
suggest that resveratrol does not increase PON1 lev-
els in the rat model; (2) the compound we used was of 
commercial origin, as a food additive, and as such con-
tains several other compounds besides resveratrol. This 
may have influenced our results; (3) in this preliminary 
study pre-treatment was not accompanied by a stand-
ard antidotal treatment post exposure. One may argue 
that it should be tested in a protocol that includes post-
exposure treatment. However, one of the goals in finding 
a new pre-treatment compound is to show it can exert its 
beneficial effects without post-exposure treatment. As 
such, resveratrol pre-treatment was found to be ineffec-
tive. In case of positive results, the next step would have 
been to define dose–response curves and study its role 
in an extended protocol including post-exposure treat-
ment; (4) it has been reported that the bioavailability of 
oral resveratrol in humans is negligible, with only trace 
amounts of the original compound detected in the blood-
stream [26]. Another study in rats showed similar results 
of s relatively low bioavailability [27]. Therefore, it is pos-
sible that the method of administration we used is not 
suitable for demonstrating the full therapeutic effect of 
the compound; (5) it is possible that resveratrol does not 
influence PON-1 levels in rats. Actually, to the best of our 
knowledge, this is the first time the relation between res-
veratrol and PON-1 is studied in vivo, in rats. (6) We did 
not find any data in the literature regarding PON1 levels 
in rats over time. We speculate that aging of the rats may 
have some effect on PON1 levels but this speculation is 
not based on hard data.
In relation to the exposure protocol, 1.4LD50 of par-
aoxon is a clinically significant dose, considered to be 
relevant for testing the efficacy and the potential role of 
medical countermeasures candidates, mainly in terms of 
counteracting severe signs of poisoning and enhancing 
survival, in a sort of go-no-go approach for future stud-
ies of a compound, especially in-light of the vast efforts 
needed to complete full development and fielding.
Another issue regards the possible role of resveratrol as 
post-exposure treatment. Since exposure to NAs results 
in a fast and severe clinical deterioration, post-exposure 
treatment requirements include immediate clinical effect 
as demonstrated, for example, by the anticholinergic drug 
atropine. Unfortunately, even if a compound like resvera-
trol has a positive effect on levels of PON1, it is notable 
only after a long period-of-time, thus not relevant for 
post-exposure treatment.
Conclusions
Since no protection was afforded to pre-treated animals, 
our current results do not support the use of resveratrol 
as a pre-treatment measure against OP poisoning. How-
ever, this was a preliminary study, using a commercial 
formulation and not the pure compound. Thus, in  vivo 
research is still relevant in order to further evaluate the 
possible influence of food supplements on PON-1 activ-
ity levels and resveratrol-PON1 dose–response curve in 
particular. Once completed, these supplements may be 
tested in a more advanced protocol as a protective pro-
phylactic measure against OP poisoning.
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